Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal in the space of a week. BMS is ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Lamin Sabally and Kosy Akametu posted double-doubles to power Iona to a 71-53 victory over Niagara on Friday night. Sabally ...

Projects at Niagara Falls Memorial will include a new 430-car parking garage, wound center, vascular lab, surgical office ...